Clinical Trials Browser

Phase 2 × NIH × denileukin diftitox × Clear all

NCT00117845 2019-11-19

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

Phase 2 Terminated

17 enrolled 9 charts

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Leukemia-Lymphoma, Adult T-Cell

NCT00026429 2013-12-18

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00082914 2013-06-20

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Phase 2 Completed

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Phase 2 Completed

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

NCT00138164 2013-05-30

Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2 Completed

50 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse